Indexed with PubMed and Science Citation Index (E) 
Users online: 3238 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

Year : 2001  |  Volume : 67  |  Issue : 1  |  Page : 48-49

Limited role of calicipotriol in inflammatory linear verrucous epidermal naevus

Department of Dermatology & Venereology, AIIMS New Delhi 110029, India

Correspondence Address:
Department of Dermatology & Venereology, AIIMS New Delhi 110029, India

How to cite this article:
Garg T, Khaitan BK, Sood A. Limited role of calicipotriol in inflammatory linear verrucous epidermal naevus. Indian J Dermatol Venereol Leprol 2001;67:48-9

How to cite this URL:
Garg T, Khaitan BK, Sood A. Limited role of calicipotriol in inflammatory linear verrucous epidermal naevus. Indian J Dermatol Venereol Leprol [serial online] 2001 [cited 2019 Oct 17];67:48-9. Available from: http://www.ijdvl.com/text.asp?2001/67/1/48/8139

To the Editor,
A 2-year-old boy presented with a moderately itchy linear plaque on the trunk extending from the lower back to the lower leg on the posterior aspect. The lesion was first noticed at birth on the leg and it gradually extended proximally and distally as a lin­ear band. There was no family history of similar dis­ease or psoriasis. Examination showed erythematous, verrucous papules with mild scaling coalescing to from plaques in a linear arrangement extending from the right side of the lower back along the right buttock,thigh and leg upto the right ankle. The boy was otherwise in good health and systemic exami­nation revealed no abnormality. Histopathology from the lesion showed hyperkeratosis with foci of parkeratosis and irregular acanthosis. In the upper dermis there were large and small aggregates of lym­phocytes and histiocytes. The clinical and histologi­cal features were consistent with the diagnosis of psoriasiform type of inflammatory linear verrucous epidermal naevus (ILVEN).
He was treated with topical betamethasone valerate 0.12% twice daily for 5 months. There was an initial improvement in the form of reduction of erythema and symptomatic relief in itching but subsequently the lesion stopped responding and there was further progression of the induration and scal­ing. Thereafter a combination of topical 0.05% be­tamethasone dipropionate with 3% salicylic acid oint­ment was tried for 4 weeks with no improvement.
He was then treated with application of 0.05% calcipotriol ointment twice a day. After 4 weeks there was about 50% flattening of the lesion and signifi­cant reduction in the erythema. After 16 weeks of treatment there was complete flattening of the le­sions, with remaining hypopigmentation and mini­mal erythema. Application of calcipotriol was stopped thereafter, a repeat biopsy was taken which showed reduction in hyperkeratosis, foci of parakeratosis, acanthosis and perivascular dermal inflammation.
After 3 weeks papules started reappearing on the same sites. As there was progression of the lesions, application of calcipotriol was restarted and continued for 4 months with significant flattening of the lesions. Then the treatment was discontinued. After another two months the lesions recurred. Calcipotriol application was restarted but the fre­quency of application was reduced to once every al­ternate day. There was partial regression of the lesion.
There is no definite medical treatment for ILVEN. Calcipotriol is one of the modalities suggested for the treatment of ILVEN. A few cases have been reported in the literature with some beneficial effect of calcipotriol in ILVEN.[1],[2],[3] In these reports,lesions showed significant improvement in 4 weeks. But fol­low-up period was rather short varying from 4-12 weeks. In our case,we followed the patient for more than 2 years. Our patient also had significant re­sponse after 4 weeks and complete flattening of the lesions after 16 weeks. But on stopping the treatment,there was recurrence of the lesions and to maintain the beneficial effect regular and long­term use of topical calcipotriol was required. However,because of the high cost of the drug,this may not be possible and there are known side ef­fects of systemic absorption of calcipotriol if used for a prolonged period.
Other treatment modalities described for the treatment of ILVEN are topical corticosteroids, topi­cal retinoids, dithranol, cryotherapy, flash lamp pumped pulsed tunable dye laser.[4] Recurrence of the lesions remains a major problem with all these thera­peutic modalities except in situations where physical destruction with cryotherapy or laser is deep enough to leave behind significant scars. With calcipotriol too, not only is the cost a limiting factor, but regular or intermittent treatment with calcipotriol brings the pa­tient under temporary remission only. 

   References Top

1.Micali G, Nasca MR,Musumeci ML. Effect of topical calcipotriol on inflammatory linear verrucous epidermal naevus. Pediatr Dermatol 1995; 12: 386-387.  Back to cited text no. 1    
2.Gatti S, Carrozzo AM, Orlandi A et al. Treatment of inflammatory linear verrucous epidermal naevus with calcipotriol. Br J Dermatol 1995; 132: 837-832.  Back to cited text no. 2    
3.Mitsuhashi Y, Katagiri Y, Kondo S.Treatment of inflammatory linear verrucous epidermal naevus with topical vitamin D3. Br J Dermatol 1997; 136: 134-135.  Back to cited text no. 3    
4.Rulo HFC, Van de Kerkhof PCM. Treatment of inflammatory linear verrucous epidermal naevus. Dermatologica 1991; 182: 112 - 114.  Back to cited text no. 4    


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow